Finance

Lists
Why is ELVN down 2,42%?
Dive Deeper
ELVN:NASDAQ
Enliven Therapeutics Inc
USD 47,62
-2,42%
(-1,18) 1D
USD 47,62
0,00% (0,00)
After hours
Closed: 16 Nov., 16:00:01 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ELVN...
Open
USD 48,58
High
USD 48,90
Low
USD 47,30
Mkt. cap
3,50 mjd
Avg. vol.
1,50 m
Volume
694,28 k
52-wk high
USD 62,32
52-wk low
USD 14,78
EPS
-USD 1,70
Beta
0,34
Shares outstanding
73,60 m
No. of employees
65
Open
USD 48,58
High
USD 48,90
Low
USD 47,30
Mkt. cap
3,50 mjd
Avg. vol.
1,50 m
Volume
694,28 k
52-wk high
USD 62,32
52-wk low
USD 14,78
EPS
-USD 1,70
Beta
0,34
Shares outstanding
73,60 m
No. of employees
65
News stories
From web sources and news partners
About Enliven Therapeutics Inc
CEO-
Employees65
Founded2016
HeadquartersBoulder, Colorado, Verenigde State van Amerika
SectorHealth Care
IndustryPharmaceutical industry
Analyst ratings
Based on 10 analysts giving stock ratings to ELVN in the past 3 months
Strong buy
Buy
10
Hold
0
Sell
0
12-month forecast
Based on 10 Wall Street analysts offering 12 month price targets for ELVN in the last 3 months.
Highest
Current USD 47,62
USD 82,00 (+72,20%)
Average
USD 74,88 (+57,24%)
Lowest
USD 70,00 (+47,00%)
Analyst
Recommendation
Action
Price target
Projected
Date
Robert Burns
H.C. Wainwright
Buy
Reiterated
USD 73,00
+53,3%
11/13/2026
Boris Peaker
JonesTrading
Buy
Maintained
USD 70,00
+47%
11/06/2026
Michael Schmidt
Guggenheim
Buy
Maintained
USD 78,00
+63,8%
11/06/2026
Dara Azar
Stifel Nicolaus
Buy
Maintained
USD 82,00
+72,2%
11/05/2026
Etzer Darout
Barclays
Buy
Maintained
USD 78,00
+63,8%
11/05/2026
Phil Nadeau
TD Cowen
Buy
Maintained
-
-
10/07/2026
Andy Hsieh
William Blair
Buy
Reiterated
-
-
10/06/2026
Sean Laaman
Morgan Stanley
Buy
Initiated
USD 70,00
+47%
10/05/2026
Priyanka Grover
J.P. Morgan
Buy
Initiated
USD 75,00
+57,5%
10/01/2026
Salim Syed
Mizuho Securities
Buy
Maintained
USD 73,00
+53,3%
08/17/2026
Sam Slutsky
LifeSci Capital
Buy
Reiterated
USD 70,00
+47%
08/08/2026
Colleen M. Kusy
Robert W. Baird
Buy
Maintained
USD 75,00
+57,5%
08/06/2026
Salveen Richter
Goldman Sachs
Buy
Reiterated
USD 80,00
+68%
08/05/2026
Kaveri Pohlman
Clear Street
Buy
Reiterated
USD 68,00
+42,8%
08/06/2026
Unknown Analyst
Jefferies
Buy
Maintained
USD 59,00
+23,9%
06/15/2026
Soumit Roy
JonesTrading
Buy
Maintained
USD 45,00
-5,5%
04/06/2026
Last report
05 Nov. 2026
Fiscal period
Q3 2026
-USD 0,36 / -USD 0,43
+16,89%beat
Revenue / Est. (USD)
- / 0,00
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Des. 2025
Mrt. 2026
Jun. 2026
Sep. 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
21,24 m
20,69 m
29,00 m
28,02 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
13,04 m
7,14 m
8,21 m
8,02 m
Operating expense
34,28 m
27,82 m
37,21 m
36,04 m
Total operating expenses
34,28 m
27,82 m
37,21 m
36,04 m
Operating income
-34,28 m
-27,82 m
-37,21 m
-36,04 m
Other non operating income
-
-
-8,00 k
-11,00 k
EBT including unusual items
-29,67 m
-23,63 m
-32,48 m
-27,70 m
EBT excluding unusual items
-29,67 m
-23,63 m
-32,48 m
-27,70 m
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-29,67 m
-23,63 m
-32,48 m
-27,70 m
Net profit margin
-
-
-
-
Earnings per share
-0,48
-0,38
-0,49
-0,36
Interest and investment income
4,62 m
4,20 m
4,73 m
8,35 m
Interest expense
-
-
-
-
Net interest expenses
4,62 m
4,20 m
4,73 m
8,35 m
Depreciation and amortization charges
-
-
-
-
EBITDA
-34,24 m
-27,81 m
-37,20 m
-36,03 m
Gain or loss from assets sale
106,00 k
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google-programme